Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

181. Low molecular weight heparins for secondary prevention of symptomatic venous thromboembolism in patients with cancer

Low molecular weight heparins for secondary prevention of symptomatic venous thromboembolism in patients with cancer Low molecular weight heparins for secondary prevention of symptomatic venous thromboembolism in patients with cancer | Therapeutics Initiative Independent Healthcare Evidence > > Low molecular weight heparins for secondary prevention of symptomatic venous thromboembolism in patients with cancer Background information of the condition Venous thromboembolism (VTE) in patients (...) molecular weight heparins (LMWHs) have fewer drug interactions and do not require monitoring of bleeding time. The Therapeutics Initiative has systematically reviewed Dalteparin for this indication. However, other LMWHs have also been studied in clinical trials in this population and are known to be in common use in British Columbia. Therefore, a systematic review of all randomized clinical trials comparing all LMWHs vs. OAC was conducted. Drug [Product monograph] Categorization: LMWHs are categorized

2007 Therapeutics Letter

182. Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis

Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis Shorr A F, Jackson W L, Weiss B M, Moores L K Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined low molecular weight heparin (LMWH) compared with unfractionated heparin (UFH) for deep vein thrombosis (DVT) prophylaxis in hospitalised patients. Type of intervention Primary prevention

2007 NHS Economic Evaluation Database.

183. Strategies for the management of suspected heparin-induced thrombocytopenia: a cost-effectiveness analysis

Strategies for the management of suspected heparin-induced thrombocytopenia: a cost-effectiveness analysis Strategies for the management of suspected heparin-induced thrombocytopenia: a cost-effectiveness analysis Strategies for the management of suspected heparin-induced thrombocytopenia: a cost-effectiveness analysis Patrick A R, Winkelmayer W C, Avorn J , Fischer M A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of four strategies for the diagnosis and treatment of heparin-induced thrombocytopenia (HIT). Testing for HIT in critical care patients was found not likely to be cost-effective, except in high-prevalence settings, which did favour strategies including testing and a more

2007 NHS Economic Evaluation Database.

184. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma

A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma Lynd L D, Goeree R, Crowther M (...) A, O'Brien B J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of enoxaparin compared with unfractionated heparin (UH) for the secondary prevention of deep vein thrombosis in patients who had

2007 NHS Economic Evaluation Database.

185. Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery

Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism (...) of asymptomatic and symptomatic VTE for ENO, and relative efficacy of FON. However, FON remained dominant or very cost-effective in all circumstances. Authors' conclusions The authors concluded that prophylactic FON was more effective and less expensive than ENO in hip fracture surgery from the perspective of the Swedish health care system. CRD commentary Interventions: The authors justified their selection of the comparators, in that ENO was the most commonly used low molecular weight heparin, and FON

2007 NHS Economic Evaluation Database.

186. Does use of the Hepcon® point-of-care coagulation monitor to optimise Heparin and Protamine dosage for cardiopulmonary bypass decrease bleeding and blood and blood product requirements in adult patients undergoing cardiac surgery?

Does use of the Hepcon® point-of-care coagulation monitor to optimise Heparin and Protamine dosage for cardiopulmonary bypass decrease bleeding and blood and blood product requirements in adult patients undergoing cardiac surgery? BestBets: Does use of the Hepcon® point-of-care coagulation monitor to optimise Heparin and Protamine dosage for cardiopulmonary bypass decrease bleeding and blood and blood product requirements in adult patients undergoing cardiac surgery? Does use of the Hepcon® (...) point-of-care coagulation monitor to optimise Heparin and Protamine dosage for cardiopulmonary bypass decrease bleeding and blood and blood product requirements in adult patients undergoing cardiac surgery? Report By: Khairul Anuar Abdul Aziza, Omar Masooda, J. Andreas Hoschtitzkya, Andrew Ronald - Specialist Registrars in Cardiothoracic Surgery, Consultant in Cardiothoracic Surgery Search checked by Joel Dunning - Cardiothoracic Registrar RCS Institution: Department of Cardiothoracic Surgery

2006 BestBETS

187. Review: low molecular weight heparin reduces recurrent venous thromboembolism better than unfractionated heparin Full Text available with Trip Pro

Review: low molecular weight heparin reduces recurrent venous thromboembolism better than unfractionated heparin Review: low molecular weight heparin reduces recurrent venous thromboembolism better than unfractionated heparin | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: low molecular weight heparin reduces recurrent venous thromboembolism better than unfractionated heparin Article Text Therapeutics Review: low molecular weight

2006 Evidence-Based Medicine

188. Readmission after hysterectomy and prophylactic low molecular weight heparin: retrospective case-control study. Full Text available with Trip Pro

Readmission after hysterectomy and prophylactic low molecular weight heparin: retrospective case-control study. To determine whether use of tinzaparin, a low molecular weight heparin introduced for prophylactic management of deep vein thrombosis, increases the risk of serious postoperative bleeding leading to a higher than expected 28 day readmission rate after discharge for hysterectomy.Retrospective case-control study using computerised hospital inpatient data and review of case (...) to 4.05) after adjustment for type of operation, age, and type of pain relief.In the prophylactic treatment of thromboembolic disease after hysterectomy, compared with calci-heparin, tinzaperin is associated with a twofold increase in risk of serious postoperative bleeding.

2006 BMJ

189. Review: no evidence exists that thrombolysis is better than heparin for reducing the risk of recurrent pulmonary embolism and death Full Text available with Trip Pro

Review: no evidence exists that thrombolysis is better than heparin for reducing the risk of recurrent pulmonary embolism and death Review: no evidence exists that thrombolysis is better than heparin for reducing the risk of recurrent pulmonary embolism and death | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: no evidence exists that thrombolysis is better than heparin for reducing the risk of recurrent pulmonary embolism and death

2006 Evidence-Based Nursing

190. Review: thrombolytic treatment does not reduce the risk of recurrent pulmonary embolism and death more than heparin Full Text available with Trip Pro

Review: thrombolytic treatment does not reduce the risk of recurrent pulmonary embolism and death more than heparin Review: thrombolytic treatment does not reduce the risk of recurrent pulmonary embolism and death more than heparin | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: thrombolytic treatment does not reduce the risk of recurrent pulmonary embolism and death more than heparin Article Text Therapeutics Review: thrombolytic

2006 Evidence-Based Medicine

191. Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study. Full Text available with Trip Pro

Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study. To find out what inpatients with advanced cancer who are receiving palliative care think about the effect of thromoprophylaxis on overall quality of life.Qualitative study using audiotaping of semistructured interviews.Regional cancer centre in Wales.28 inpatients with advanced metastatic cancer receiving palliative care and low molecular weight heparin.Recurring themes (...) on the effect of thromboprophylaxis on overall quality of life.Major emerging themes showed that patients knew about the risks of venous thromboembolism and the purpose of treatment with heparin. Media coverage had raised awareness about venous thromboembolism, and many had previous experience of thromboprophylaxis. All found low molecular weight heparin an acceptable intervention, and many said that it improved their quality of life by giving them a feeling of safety and reassurance. Antiembolic stockings

2006 BMJ

192. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. Full Text available with Trip Pro

Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. Unfractionated heparin is often used as adjunctive therapy with fibrinolysis in patients with ST-elevation myocardial infarction. We compared a low-molecular-weight heparin, enoxaparin, with unfractionated heparin for this purpose.We randomly assigned 20,506 patients with ST-elevation myocardial infarction who were scheduled to undergo fibrinolysis to receive enoxaparin throughout the index (...) hospitalization or weight-based unfractionated heparin for at least 48 hours. The primary efficacy end point was death or nonfatal recurrent myocardial infarction through 30 days.The primary end point occurred in 12.0 percent of patients in the unfractionated heparin group and 9.9 percent of those in the enoxaparin group (17 percent reduction in relative risk, P<0.001). Nonfatal reinfarction occurred in 4.5 percent of the patients receiving unfractionated heparin and 3.0 percent of those receiving enoxaparin

2006 NEJM Controlled trial quality: predicted high

193. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. Full Text available with Trip Pro

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. Despite its limitations, unfractionated heparin has been the standard anticoagulant used during percutaneous coronary intervention (PCI). Several small studies have suggested that intravenous enoxaparin may be a safe and effective alternative. Our primary aim was to assess the safety of enoxaparin as compared with that of unfractionated heparin in elective PCI.In this prospective, open-label, multicenter (...) , randomized trial, we randomly assigned 3528 patients with PCI to receive enoxaparin (0.5 or 0.75 mg per kilogram of body weight) or unfractionated heparin adjusted for activated clotting time, stratified according to the use or nonuse of glycoprotein IIb/IIIa inhibitors. The primary end point was the incidence of major or minor bleeding that was not related to coronary-artery bypass grafting. The main secondary end point was the percentage of patients in whom the target anticoagulation levels were

2006 NEJM Controlled trial quality: predicted high

194. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. Full Text available with Trip Pro

Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. When unfractionated heparin is used to treat acute venous thromboembolism, it is usually administered by intravenous infusion with coagulation monitoring, which requires hospitalization. However, subcutaneous administration of fixed-dose, weight-adjusted, unfractionated heparin may be suitable for inpatient and outpatient treatment of venous (...) thromboembolism.To determine if fixed-dose, weight-adjusted, subcutaneous unfractionated heparin is as effective and safe as low-molecular-weight heparin for treatment of venous thromboembolism.Randomized, open-label, adjudicator-blinded, noninferiority trial of 708 patients aged 18 years or older with acute venous thromboembolism from 6 university-affiliated clinical centers in Canada and New Zealand conducted from September 1998 through February 2004. Of the randomized patients, 11 were subsequently excluded

2006 JAMA Controlled trial quality: predicted high

195. The uses of heparin to treat burn injury

The uses of heparin to treat burn injury The uses of heparin to treat burn injury The uses of heparin to treat burn injury Oremus M, Hanson M, Whitlock R, Young E, Gupta A, Dal Cin A, Archer C, Raina P CRD summary This review assessed the efficacy and safety of heparin in the treatment of burns. The authors concluded that there was insufficient evidence to support the use of heparin, but that further specific randomised trials should be conducted. This is a generally well-conducted review (...) and the conclusions are likely to be reliable. Authors' objectives To assess the evidence for the benefits and harms of heparin in thermal injury care in relation to different methods of application, the effect of different types or degrees of burn, and comparison with current treatment which does not include heparin; and to identify contraindications for the use of heparin. Searching MEDLINE (from 1966), EMBASE (from 1980), CINAHL (from 1982), the Cochrane CENTRAL Register (from 1995), Web of Science (from 1976

2006 DARE.

196. Patency of arterial catheters with heparinized solutions versus non-heparinized solutions: a review of the literature

Patency of arterial catheters with heparinized solutions versus non-heparinized solutions: a review of the literature Patency of arterial catheters with heparinized solutions versus non-heparinized solutions: a review of the literature Patency of arterial catheters with heparinized solutions versus non-heparinized solutions: a review of the literature Lapum J L CRD summary The author concluded that the strength of individual study results is limited by the lack of rigour in the study design (...) J L. Patency of arterial catheters with heparinized solutions versus non-heparinized solutions: a review of the literature. Canadian Journal of Cardiovascular Nursing 2006; 16(2): 64-70 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Anticoagulants /administration & Arteries; Catheterization, Peripheral /adverse effects /nursing; Catheters, Indwelling /adverse effects; Clinical Nursing Research; Equipment Failure; Evidence-Based Medicine; Heparin /administration & Humans; Nursing

2006 DARE.

197. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency

Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency Lim W, Dentali F, Eikelboom J W, Crowther M A CRD summary This well-conducted review assessed anti-Xa heparin levels and bleeding events in patients with severe renal insufficiency who were (...) receiving low molecular weight heparin. It concluded that standard therapeutic doses of enoxaparin led to higher anti-Xa heparin levels and increased the risk of major bleeding. These conclusions are limited by the observational nature of the included studies. Authors' objectives To compare levels of anti-Xa heparin and the risk of bleeding in patients with a creatinine clearance of up to 30 mL/minute (mL/min), who were being treated with low molecular weight heparin (LMWH), with those with a creatinine

2006 DARE.

198. The uses of heparin to treat burn injury

The uses of heparin to treat burn injury The uses of heparin to treat burn injury The uses of heparin to treat burn injury Oremus M, Hanson M, Whitlock R, Young E, Gupta A, Dal Cin A, Archer C, Raina P Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Oremus M, Hanson M, Whitlock R, Young E, Gupta A, Dal Cin A, Archer C, Raina P. The uses (...) of heparin to treat burn injury. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 148. 2006 Authors' objectives The aim of this report is to assess the evidence for using heparin in the treatment of burn injury or the complications of burn injury in adults and children. Authors' conclusions There is no strong evidence in the 19 abstracted articles to suggest that heparin should be used in the treatment of burn injury on account of its non

2006 Health Technology Assessment (HTA) Database.

199. A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins: enoxaparin, nadroparin and dalteparin - the ESCAPe-END study

A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins: enoxaparin, nadroparin and dalteparin - the ESCAPe-END study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.

200. Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA study Full Text available with Trip Pro

Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA study Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA study Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice (...) Treatment. Economic study type Cost-effectiveness analysis. Study population Patients with an acute VTE event who were over 18 years old were included in the study. Patients were excluded if they were hypersensitive to heparin or other pig-derived substances, had a history of documented or suspected immune-mediated heparin-induced thrombocytopaenia (HIT), had an active haemorrhage, had a high risk of bleeding, or severe impairment of liver and pancreas. Further criteria for exclusion were injuries

2006 NHS Economic Evaluation Database.